Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | RRM2 | P31350 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL164139 | 0.98 | LOXL2 (0.47) | LOXL2BRD4CHEK1GRM2HRH3 | |
| Hydrochloric Acid SCHEMBL3176304 | 0.98 | LOXL2 (0.47) | LOXL2BRD4CHEK1GRM2HRH3 | |
| SCHEMBL3051067 | 0.84 | CHRNA7 (0.41) | LOXL2CHEK1GRM2 | |
| SCHEMBL21491789 | 0.79 | BRD4 (0.38) | LOXL2BRD4EGLN2 | |
| SCHEMBL24146512 | 0.79 | GAA (0.38) | BRD4CHEK1GRM2ALOX5APFEN1 | |
| SCHEMBL453184 | 0.79 | BRD4 (0.39) | BRD4CHEK1GRM2AREGLN2 | |
| SCHEMBL507109 | 0.79 | AR (0.41) | BRD4CHEK1GRM2ALOX5APFEN1 | |
| SCHEMBL2643631 | 0.79 | BRD4 (0.36) | BRD4CHEK1GRM2ALOX5APFEN1 | |
| SCHEMBL453185 | 0.79 | CHEK1 (0.44) | BRD4CHEK1GRM2AREGLN2 | |
| SCHEMBL452013 | 0.79 | BRD4 (0.36) | BRD4CHEK1GRM2NSD2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4702028-A1 | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702023-A1 | CRYSTALLINE PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITOR AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | disclosed |
| EP-4683919-A1 | VANIN-1 INHIBITORS | Athos Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015349-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20250066353-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250034132-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-30 | — | — | US | disclosed |
| US-12209101-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-28 | — | — | US | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| EP-1202988-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010847-A2 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-15 | — | — | WO | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5932567-A | Thrombin inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
| EP-0809651-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-03 | — | — | EP | disclosed |
| EP-0773955-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996024609-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |
| WO-1995035309-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015349-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | CBR1, HCCS, NCOR1 | LOXL2 2776/4885BRD4 350/4885CHEK1 3669/4885 |
| US-20250066353-A1 | VANIN-1 INHIBITORS | VCAM1, TMBIM6, VNN1 | LOXL2 714/4885BRD4 85/4885CHEK1 1318/4885 |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | LOXL2 2059/4885BRD4 615/4885CHEK1 323/4885 |
| US-20250034132-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN3, EGLN2, EGLN1 | LOXL2 698/4885BRD4 161/4885CHEK1 4537/4885 |
| US-12209101-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN2, EGLN3, EGLN1 | LOXL2 1719/4885BRD4 480/4885CHEK1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.